As the popularity of GLP-1 receptor agonists (GLP1ra)—such as semaglutide and tirzepatide—continues to skyrocket, a complex medical frontier is emerging in the operating rooms of plastic surgeons worldwide. While these medications have revolutionized the treatment of obesity and type 2 diabetes, their physiological impact on surgical recovery remains a subject of intense scrutiny. A groundbreaking study published in the April issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS), now sheds light on how these drugs influence the outcomes of patients undergoing panniculectomy—a common body contouring procedure to remove excess abdominal skin after massive weight loss.
The Intersection of Pharmacotherapy and Plastic Surgery
Body contouring is a cornerstone of reconstructive surgery for patients who have achieved significant weight loss, whether through bariatric intervention or lifestyle modification. The procedure, specifically a panniculectomy, is designed to excise the "pannus"—the apron of loose, hanging skin and adipose tissue that remains in the lower abdomen. For many patients, this surgery is not merely cosmetic; it is a functional necessity that alleviates skin irritation, chronic infections, and physical discomfort.
However, the rapid adoption of GLP-1 medications has introduced a new variable into the perioperative landscape. Because these drugs act on the central nervous system to regulate appetite and influence metabolic processes, surgeons have long hypothesized that they might alter the body’s inflammatory response and wound-healing capacity. With plastic surgeons increasingly prescribing these medications to help patients reach an optimal weight before surgery, understanding their safety profile has become an urgent clinical priority.
Chronology: A Decade of Data in West Virginia
The study, led by Dr. Zachary Andrew Koenig and his colleagues at the West Virginia University School of Medicine, provides a unique, long-term perspective on this clinical phenomenon. By analyzing a cohort of 373 patients who underwent nonbariatric panniculectomy between 2013 and 2023, the researchers were able to observe the evolution of practice patterns in real time.
The Rise of GLP-1 Integration
- 2013–2018: During the early years of the study period, the use of GLP-1 receptor agonists among the surgical cohort was relatively sparse, consistent with broader national prescribing trends at the time.
- 2019–2021: As the medications gained FDA approval for chronic weight management, researchers observed a steady uptick in preoperative use among candidates for body contouring.
- 2022–2023: The study period concluded with a sharp, statistically significant increase in the percentage of patients taking GLP-1s prior to surgery. By the end of the study, nearly 21.7% of all patients undergoing panniculectomy were utilizing these medications.
The researchers specifically chose to isolate the study to nonbariatric and non-hernia related cases to ensure that the outcomes were not confounded by the complex physiological shifts associated with stomach-reduction surgeries or abdominal wall reconstruction. This meticulous filtering allowed the team to pinpoint the specific effects of the medication on the skin and soft tissues during the healing process.
Supporting Data: The Dual-Edged Sword of Healing
The findings presented by Dr. Koenig’s team reveal a "complex and nuanced interplay" between pharmacological weight management and surgical recovery. The data indicates that while GLP-1 medications do not appear to increase the overall risk of major surgical failure or death, they do produce distinct, measurable differences in how the body repairs itself.
The Delayed Healing Phenomenon
One of the most significant findings was the incidence of delayed wound healing. Among patients taking GLP-1 medications, the rate of delayed healing reached 18.5%. In contrast, the control group (those not taking GLP-1s) experienced a rate of just 7.5%. This statistical variance suggests that these drugs may influence the collagen production or the vascularity of the skin, potentially slowing down the closure of surgical sites.
The Seroma Paradox
Perhaps the most surprising discovery was the reduction in seroma formation. A seroma is a common and often frustrating complication in body contouring, characterized by the buildup of serous fluid under the skin where tissue was removed. The study found that GLP-1 users had a significantly lower rate of seroma (4.9%) compared to the non-GLP-1 group (14.0%). While the exact mechanism remains under investigation, some experts speculate that the metabolic changes induced by GLP-1s might alter the inflammatory response that typically leads to fluid accumulation, or perhaps the systemic effects of the medication influence lymphatic drainage.
Parity in Major Complications
Crucially, the study found no significant difference between the two groups regarding:
- Wound Dehiscence: The reopening of a closed surgical wound.
- Infection: Post-operative bacterial colonization at the surgical site.
- Rehospitalization Rates: The frequency of patients requiring a return to the hospital for acute care following their initial surgery.
Official Responses and Clinical Implications
The implications of this research are profound for both surgeons and their patients. Dr. Zachary Andrew Koenig noted, "As GLP-1 receptor agonist medications become increasingly integrated into the care of patients undergoing body contouring, our findings suggest that these drugs may have subtle effects on wound healing, even if they don’t increase overall surgical risks."
For the plastic surgery community, the takeaway is clear: the perioperative use of GLP-1s is likely safe in the context of avoiding catastrophic outcomes, but it requires a "proactive management" approach. This means that surgeons may need to adjust their postoperative care plans—perhaps by extending the monitoring period for wound closure or being more aggressive with skin care regimens for patients on these medications.
The study also underscores the unique nature of the patient population in West Virginia. Because the state carries one of the highest rates of GLP-1 prescriptions in the United States, the findings may serve as a "canary in the coal mine" for the rest of the country. As these drugs become ubiquitous, other regions will likely see similar patterns in their plastic surgery clinics.
Moving Toward Formalized Guidelines
The research concludes with a call to action. The current landscape is evolving faster than formal clinical guidelines can keep pace. The ASPS and other professional bodies are tasked with the difficult job of determining whether patients should cease GLP-1 use before surgery—and for how long.
If a patient stops taking their medication too early, they may risk weight regain or the return of metabolic instability. If they stay on the medication, they may face the higher risk of delayed wound healing identified in this study. The "nuanced interplay" described by the researchers suggests that a one-size-fits-all policy may be inadequate. Instead, surgeons are encouraged to engage in shared decision-making, weighing the benefits of metabolic optimization against the specific risk profile of the individual patient.
Future research is expected to focus on the biological mechanisms behind these findings. Researchers hope to determine whether the delay in wound healing is a result of altered glucose metabolism, reduced local inflammation, or direct effects on fibroblast activity. Until such studies are completed, the medical community will rely on data like that provided in the April issue of Plastic and Reconstructive Surgery® to guide their practice.
Conclusion: A New Era in Surgical Preparation
The integration of GLP-1 receptor agonists into the surgical pathway represents a significant shift in how plastic surgeons prepare patients for major procedures. While the data suggests that these medications are not a contraindication for surgery, they do alter the recovery narrative.
As surgeons look to the future, the focus will likely move toward personalized perioperative plans. By identifying the specific risks and benefits associated with GLP-1 usage, practitioners can continue to provide high-quality care to patients who have worked hard to lose weight and are seeking the final step in their transformation: body contouring. The path forward is one of cautious optimism, grounded in rigorous research and a commitment to patient safety in an era of rapid medical innovation.
For more information on these findings, the full study, "Perioperative GLP-1 Receptor Agonist Use and Surgical Outcomes in Nonbariatric Abdominal Panniculectomy: A 10-Year Retrospective Analysis," is available in the April issue of Plastic and Reconstructive Surgery® (doi: 10.1097/PRS.0000000000012405).
About the Author
